Biologic therapy transitions for pediatric Crohn's disease

Biologic Therapy Transitions for Pediatric Crohn’s Disease

The clinical presentation may reflect primary non-response, secondary loss of response, inadequate drug exposure, anti-drug antibodies, mechanistic failure, or an inflammatory process that is no longer being driven predominantly by the pathway the current treatment was designed to block.

That distinction determines the management pathway. In pediatric inflammatory bowel disease, infliximab and adalimumab remain the principal first-line anti-TNF biologics for induction and maintenance of remission. Yet approximately one-third of children with inflammatory bowel disease experience either no initial response or a later loss of response to anti-TNF therapy. For these patients, biologic therapy transition options for pediatric Crohn’s disease increasingly include another anti-TNF agent, a switch to a different biologic class, or, in highly refractory disease, a carefully supervised combination of targeted therapies.

The appropriate transition depends less on the label of “biologic failure” than on why the current treatment failed, what objective inflammation remains, and how urgently disease control is needed.

The first question: what kind of anti-TNF failure has occurred?

Before changing therapy, we need to establish whether the child has active Crohn’s inflammation and whether the current biologic has been given an adequate opportunity to work. Symptoms alone are not sufficient. Abdominal pain, loose stools, fatigue, reduced appetite, and slowed growth can reflect active disease, but they may also persist after inflammation has improved or arise from complications such as stricturing, infection, bile acid diarrhea, or functional gastrointestinal symptoms.

A transition should therefore begin with a clinical reassessment that may include:

• Symptom pattern, stool frequency, nocturnal symptoms, bleeding, appetite, and abdominal pain.
• Growth velocity, weight trajectory, pubertal development, and school or daily activity.
• Laboratory markers of inflammation and nutritional status.
• Fecal inflammatory markers when used within the treating team’s monitoring strategy.
• Endoscopic, histologic, or imaging evidence when the clinical picture requires confirmation.
• Drug concentrations and anti-drug antibodies when therapeutic drug monitoring is available and relevant.

This assessment separates several clinically different situations.

Primary non-response

Primary non-response means that the child did not achieve a meaningful clinical or objective response during induction. The key issue is whether the biologic was exposed adequately and whether the treatment target was appropriate. Persistent inflammation despite sufficient drug exposure suggests that the TNF pathway may not be the dominant driver of disease activity, although interpretation depends on timing, disease severity, and the endpoint being measured.

Secondary loss of response

Secondary loss of response occurs after an initial improvement. The child may relapse months or years into treatment, with renewed diarrhea, abdominal pain, bleeding, weight loss, anemia, or elevated inflammatory markers.

This pattern can result from declining drug exposure, increased clearance during inflammatory disease, immunogenicity, underdosing as the child grows, or a change in the biology of the disease. Secondary loss of response is not automatically a reason to abandon the entire drug class. In some cases, optimizing the current regimen or using another anti-TNF agent remains clinically reasonable.

Pharmacokinetic failure

Pharmacokinetic failure generally refers to inadequate drug exposure. The medication may be cleared too rapidly, neutralized by anti-drug antibodies, or insufficient for the child’s current inflammatory burden. In this setting, the biologic may still be capable of controlling the disease if exposure can be restored.

This is where therapeutic drug monitoring for pediatric biologics can make the transition decision more precise. A low concentration, particularly when accompanied by active inflammation, may point toward dose optimization, interval adjustment, or a strategy addressing immunogenicity rather than an immediate move to a different mechanism.

Pharmacodynamic failure

Pharmacodynamic failure is different. Here, the drug concentration is adequate, but the disease remains active. The biological target may no longer be sufficient to control the inflammatory cascade, or the child’s Crohn’s disease may not be responding to that mechanism despite appropriate exposure.

The distinction matters because switching from adalimumab to infliximab after pharmacodynamic failure may produce a different result from switching after antibody-mediated clearance or very low drug levels. The evidence is not uniform across every failure phenotype, and no transition strategy is universally superior.

A biologic failure is not one event but a clinical pattern: the reason for failure should guide the next mechanism.

When switching from adalimumab to infliximab may be the stronger option

Infliximab and adalimumab are both anti-TNF agents, but they are not interchangeable in every practical respect. They differ in formulation, route of administration, dosing logistics, infusion requirements, and the way clinicians can observe treatment delivery. Infliximab is administered by intravenous infusion, while adalimumab is administered subcutaneously. For some families, that difference is a burden; for others, supervised infusion provides greater confidence that the full dose has been received.

A pediatric cohort examining adalimumab pharmacodynamic failure offers an important, specific comparison. In children with an adalimumab trough concentration of at least 7.5 µg/mL, switching to infliximab was associated with better drug sustainability than switching to ustekinumab: 88% compared with 30%. Corticosteroid-free clinical remission was also higher in the infliximab group, at 58% compared with 32%.

These findings should not be converted into a general rule that another anti-TNF agent is always preferable. The cohort addressed a particular clinical context: adalimumab pharmacodynamic failure with a documented drug concentration at or above the stated threshold. It does, however, challenge the assumption that a failure of one anti-TNF agent automatically requires leaving the class.

The practical implications are several:

1. A documented adequate adalimumab concentration changes the interpretation of failure.

If the child has active Crohn’s inflammation despite sufficient exposure, the team may consider whether infliximab could still provide a useful anti-TNF strategy, particularly when the evidence and clinical context support it.

2. Drug sustainability matters alongside initial response.

A treatment that produces remission briefly but cannot be maintained is not a successful long-term management pathway. Sustainability includes ongoing disease control, tolerability, adherence, infusion or injection feasibility, and the ability to maintain steroid-free remission.

3. The delivery model can influence real-world treatment.

Infliximab allows infusion-center administration and scheduled clinical contact. Adalimumab allows treatment at home but places more responsibility on the family. Neither model is inherently better for every child; the best option is the one that can be delivered consistently and safely.

4. The reason for failure remains central.

The result does not establish that infliximab should replace ustekinumab after every adalimumab failure, nor does it show that switching out of class is inappropriate. It supports a more differentiated conversation.

Switching out of class: ustekinumab and vedolizumab

When anti-TNF therapy is ineffective, poorly tolerated, or no longer acceptable to the family, clinicians may consider moving to a biologic with a different mechanism. Ustekinumab targets the interleukin-12/23 pathway, while vedolizumab is designed to limit gut-directed lymphocyte trafficking through the α4β7 integrin pathway.

Both are used in pediatric gastroenterology as second-line or off-label options in many settings, but the regulatory landscape must be explained clearly. Infliximab and adalimumab are the two biologic agents with formal pediatric licensing for inflammatory bowel disease referenced in the available evidence. Newer agents such as ustekinumab and vedolizumab are therefore frequently prescribed off-label in children, depending on local regulations, institutional practice, age, disease severity, and payer requirements.

That does not make them experimental in the everyday sense, but it does mean that the treating team must discuss the strength and limits of pediatric evidence, consent requirements, monitoring, and access.

Ustekinumab

Ustekinumab is often considered a leading second-line biologic option for pediatric Crohn’s disease after anti-TNF failure. Available comparative summaries describe it as generally more effective for Crohn’s disease than vedolizumab, while vedolizumab tends to have a stronger role in ulcerative colitis. These are broad clinical patterns, not guarantees for an individual child.

Ustekinumab may be considered when:

• Crohn’s inflammation remains active despite adequate anti-TNF exposure.
• The child has experienced significant intolerance or immunogenicity with anti-TNF therapy.
• A different immune target is preferred because of the prior treatment history.
• The family and clinical team are comfortable with an off-label pediatric treatment pathway where applicable.
• The disease phenotype and urgency of control fit the expected onset and monitoring plan.

One unresolved issue is the optimal therapeutic drug monitoring target for ustekinumab dosing in young children. Pediatric pharmacokinetics can be influenced by body size, inflammatory burden, albumin, prior biologic exposure, and clearance patterns. We should therefore avoid presenting a single trough concentration as a universal pediatric target when the evidence does not establish one.

Vedolizumab

Vedolizumab offers a more gut-selective mechanism, which can be attractive when the clinical team is seeking intestinal immune modulation. It is often considered more useful in ulcerative colitis than Crohn’s disease, although children with Crohn’s may still receive it after anti-TNF failure.

The decision is not based only on mechanism. Disease location, severity, previous therapies, the need for rapid control, extraintestinal manifestations, nutritional status, and the child’s practical treatment circumstances all influence the choice. A gut-selective approach may be appealing, but a slower or less predictable response in a child with severe active Crohn’s disease may alter the risk-benefit discussion.

The importance of setting expectations

Families can reasonably ask when a new biologic should begin to work, how response will be measured, and what happens if the next treatment does not succeed. These questions are part of the management pathway, not an afterthought.

A useful plan identifies:

• The symptoms that should improve first.
• The laboratory or stool markers that will be followed.
• The point at which lack of response will trigger reassessment.
• Whether endoscopy or imaging is needed to confirm healing.
• How nutritional support, iron replacement, bone health, and steroid reduction will be managed during the transition.

For a child, the meaningful outcome is not simply a lower inflammatory marker. It is restoration of growth, school participation, appetite, sleep, physical activity, and quality of life without prolonged corticosteroid exposure.

A comparison of transition strategies

Dual targeted therapy: a possible route for refractory disease

The most complex biologic therapy transition options for pediatric Crohn’s disease arise when a child has persistent objective inflammation despite sequential treatments. In these circumstances, some specialist centers are exploring dual targeted therapy, combining two biologics or a biologic with a small-molecule therapy.

This is not a routine escalation step. It is generally reserved for refractory cases in which the expected burden of uncontrolled disease is high and conventional pathways have not delivered remission. The approach may involve combinations chosen to address different parts of the immune response, but the evidence base remains considerably smaller than for single-agent anti-TNF therapy.

A systematic review and meta-analysis of 217 pediatric inflammatory bowel disease patients who had failed prior therapy reported a pooled clinical remission rate of 69%, with a 95% confidence interval of 52% to 84%. The pooled corticosteroid-free remission rate was 66%, with a 95% confidence interval of 41% to 88%. The reported pooled adverse event rate was 17%, with a 95% confidence interval of 6% to 31%.

These results are encouraging, but they need to be read with clinical caution. A pooled remission estimate from heterogeneous studies does not tell us that any specific combination will work for a particular child. The patients, disease phenotypes, prior treatments, definitions of remission, follow-up periods, and safety surveillance may differ across studies.

Dual targeted therapy also creates a more demanding monitoring environment. The team must consider:

• Baseline infection screening and vaccination status.
• Ongoing surveillance for infection and treatment-related complications.
• Laboratory monitoring tailored to the agents being used.
• Medication interactions and overlapping immunosuppression.
• The child’s nutritional state and corticosteroid exposure.
• A clear stopping or de-escalation plan if the combination is ineffective or poorly tolerated.

The unknowns are important. Long-term, multi-year safety profiles of newer interleukin-23 selective inhibitors and JAK inhibitors remain incompletely defined in pediatric Crohn’s disease cohorts. That uncertainty should be disclosed rather than softened by presenting emerging therapies as established standards.

In refractory pediatric Crohn’s disease, escalation should increase precision, not simply increase the number of immunosuppressive medicines.

How therapeutic drug monitoring supports the transition decision

Therapeutic drug monitoring is most valuable when it answers a defined clinical question. A concentration result should not be interpreted in isolation, and a number outside a local target range does not automatically determine the next therapy.

For anti-TNF treatment, the central questions are:

• Is there objective evidence of active inflammation?
• What was the drug concentration at the time of activity?
• Are anti-drug antibodies present?
• Has the child outgrown the dose or developed increased clearance?
• Was the sample collected at an appropriate point in the dosing interval?
• Is the apparent treatment failure actually driven by a complication or a non-inflammatory condition?

A low concentration with active inflammation may support dose optimization or an approach to immunogenicity. An adequate concentration with active inflammation may support a mechanistic switch, although the specific evidence for remaining within the anti-TNF class depends on the agent and failure phenotype.

The adalimumab pharmacodynamic failure data illustrate why this distinction matters. Children with a trough concentration of at least 7.5 µg/mL did not simply represent a generic group of anti-TNF non-responders. Their treatment history suggested that drug exposure was present, yet disease control remained inadequate. In that context, the observed outcomes favored switching to infliximab over ustekinumab for drug sustainability and corticosteroid-free clinical remission.

We should also remember that therapeutic drug monitoring is one part of assessment. A child with weight loss, anemia, low albumin, or elevated inflammatory markers may require an urgent treatment decision even while laboratory and pharmacologic information is being assembled. Monitoring should clarify the route forward, not become a reason to postpone necessary care.

Safety, licensing, and quality of life during escalation

Pediatric Crohn’s disease treatment decisions carry two forms of risk. The first comes from active inflammation: impaired growth, nutritional deficiency, anemia, hospitalization, stricturing or penetrating complications, and lasting effects on quality of life. The second comes from immunomodulatory treatment, including infection risk, infusion or injection reactions, immunogenicity, and uncertainty around newer therapies.

The balance cannot be reduced to choosing the least immunosuppressive option. A child with uncontrolled Crohn’s disease may face greater cumulative harm from repeated corticosteroid courses, poor nutrition, and persistent inflammation than from a well-monitored biologic strategy. The aim is durable, steroid-free control with the lowest reasonable treatment burden.

This is also where formal licensing and off-label use need to be communicated plainly. If ustekinumab, vedolizumab, a JAK inhibitor, or another newer agent is being considered outside formal pediatric licensing for the specific indication, the family should understand:

• Why the treatment is being proposed.
• What pediatric evidence exists and where it is limited.
• How consent and coverage will be handled.
• What monitoring will be performed.
• What alternatives are available.
• What would prompt discontinuation or a change in strategy.

The child’s quality of life belongs in the treatment assessment from the beginning. An infusion schedule may be difficult for one family and reassuring for another. Home injections may support independence but create adherence challenges. Repeated endoscopy may be clinically useful but burdensome. A plan that looks elegant pharmacologically may fail if it cannot be integrated into family life.

Building a durable management pathway

The strongest transition plans are staged rather than improvised. They define what is being treated, how success will be recognized, and when the next decision will be made.

A practical pathway usually includes:

1. Confirm active Crohn’s inflammation.

Do not label persistent symptoms as biologic failure without considering infection, structural complications, nutritional problems, and non-inflammatory causes.

2. Classify the treatment failure.

Separate primary non-response, secondary loss of response, pharmacokinetic failure, immunogenicity, and pharmacodynamic failure whenever the available data allow.

3. Use drug monitoring to refine the choice.

Concentration and antibody results can support optimization, another anti-TNF strategy, or a switch out of class.

4. Match the next treatment to disease urgency.

A child with severe inflammation, growth impairment, or steroid dependence may require a different pace and level of escalation from a child with mild biochemical activity.

5. Agree on objective endpoints.

Symptom improvement matters, but remission should be assessed through a combination of clinical status, growth, laboratory markers, and endoscopic or imaging findings when appropriate.

6. Plan for safety and feasibility.

Vaccination, infection screening, nutrition, adherence, infusion logistics, and family preferences all influence whether a treatment can succeed over time.

7. Reassess rather than continue indefinitely.

If the new strategy does not produce objective improvement, the team should revisit the diagnosis, mechanism, exposure, and next escalation step rather than allowing uncertainty to become prolonged corticosteroid use.

The long-term outlook

For families navigating switching biologics in pediatric IBD, the prospect of another treatment failure can be exhausting. Yet the current evidence supports a more individualized approach than a simple sequence of increasingly potent medicines.

Infliximab and adalimumab remain the established first-line biologic foundation for pediatric Crohn’s disease. When anti-TNF therapy fails, the next step may be optimization, a switch between anti-TNF agents, a move to ustekinumab or vedolizumab, or, in highly refractory disease, consideration of dual targeted therapy. The most persuasive choice depends on the type of failure, objective inflammation, drug exposure, treatment urgency, and the child’s broader clinical circumstances.

The evidence for switching from adalimumab to infliximab after pharmacodynamic failure is particularly useful because it demonstrates that staying within the same biologic class can sometimes outperform an immediate switch to a different mechanism. At the same time, second-line agents and emerging combinations are expanding the available pathway for children who do not respond to anti-TNF treatment.

Our goal is not simply to find the next medicine. It is to restore growth, reduce inflammation, avoid repeated corticosteroid exposure, protect long-term intestinal health, and give the child a sustainable quality of life. With careful classification of biologic failure, thoughtful use of therapeutic drug monitoring, and transparent discussion of off-label evidence and uncertainty, treatment transitions can become structured clinical decisions rather than a series of last-minute reactions.